Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
BRONKESE COMPOUND LINCTUS SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): BRONKESE COMPOUND LINCTUS COMPOSITION: Each 5 mL of the linctus contains: Bromhexine Hydrochloride 4,00 mg Orciprenaline Sulphate 5,00 mg Preservatives: Propyl Hydroxybenzoate 0,015% m/v Sodium Methyl Hydroxybenzoate 0,050% m/v Sucrose-free PHARMACOLOGICAL CLASSIFICATION: A 10.1 : Antitussives and Expectorants. PHARMACOLOGICAL ACTION: Bromhexine with Orciprenaline (Bronkese Compound Linctus) has mucolytic and bronchodilatory properties. INDICATIONS: BRONKESE Compound Linctus is indicated for cough associated with bronchospasm (wheeziness) and tenacious phlegm (sputum). CONTRA-INDICATIONS: Acute coronary disease and cardiac asthma. Caution should be observed in patients suffering from hyperthyroidism and/or peptic ulceration. Not to be administered concurrently with alpha and beta-blocking agents. WARNINGS: BRONKESE Compound Linctus should be avoided or used with caution in patients undergoing anaesthesia with cyclopropane, halothane or other halogenated anaesthetics, as it may induce ventricular fibrillation. An increased risk of arrhythmias may also occur if given to patients receiving cardiac glycosides, quinidine, or tricyclic antidepressants. Many sympathomimetics interact with monoamine oxidase inhibitors, and should not be given to patients receiving such treatment or within 14 days of its termination. KEEP OUT OF THE REACH OF CHILDREN DOSAGE AND DIRECTIONS FOR USE: Adults and children over 12 years: 10-20 mL three times a day. Children younger than 12 years: 5-10 mL three times a day. Infants: 2,5-5 mL three times a day. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Gastro-intestinal side-effects may occur occasionally with Bromhexine and a transient rise in serum aminotransferase value has been reported. Orciprenaline Sulphate, Read the complete document